Loading

Please wait...

Prevymis

Generic Name: letermovir (oral/injection) (le TERM oh vir)
Brand Names: Prevymis
Prevymis (letermovir) is used in the prevention of cytomegalovirus. Includes Prevymis side effects, interactions and indications.
  • Prescription Settings

Prices and coupons of Prevymis

Current Location: 20149 (Ashburn)
Change Location?

Enter your zip code


Please wait while the prices are loaded...

Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:

Drug Information:
Prevymis (letermovir) is an antiviral medicine used to help prevent cytomegalovirus (CMV) infection after a stem cell (bone marrow) transplant from a donor. Prevymis is for use in adults who are seropositive for CMV. Seropositive means that the virus is in your blood even if you do not show any symptoms of infection. A CMV-seropositive person is at risk for "reactivation" of the virus if the immune system becomes weak. While normally treatable, CMV infection can be serious in people undergoing a stem cell transplant. Learn more

Prevymis Side Effects

Prevymis Side Effects

Note: This document contains side effect information about letermovir. Some of the dosage forms listed on this page may not apply to the brand name Prevymis.

For the Consumer

Applies to letermovir: oral tablet

Other dosage forms:

  • intravenous solution

Along with its needed effects, letermovir (the active ingredient contained in Prevymis) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking letermovir:

More common

  • Bloating or swelling of the face, arms, hands, lower legs, or feet
  • rapid weight gain
  • tingling of the hands or feet
  • unusual weight gain or loss

Less common

  • Dizziness
  • fainting
  • fast, pounding, or irregular heartbeat or pulse

Some side effects of letermovir may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

  • Cough
  • diarrhea
  • headache
  • nausea
  • stomach pain
  • unusual tiredness or weakness
  • vomiting

For Healthcare Professionals

Applies to letermovir: intravenous solution, oral tablet

General

Side effects included those reported during treatment with study medication or within 2 weeks of study medication completion/discontinuation; the time for reporting side effects and laboratory abnormalities averaged about 22% longer with this drug compared to with placebo. The side effects most commonly reported included nausea, diarrhea, vomiting, peripheral edema, cough, headache, fatigue, and abdominal pain.

Hematologic

Decreased hemoglobin (less than 6.5 g/dL: 2%; 6.5 to less than 8 g/dL: 14%; 8 to less than 9.5 g/dL: 41%), platelets (less than 25,000 cells/mcL: 27%; 25,000 to less than 50,000 cells/mcL: 17%; 50,000 to less than 100,000 cells/mcL: 20%), and absolute neutrophil count (less than 500 cells/mcL: 19%; 500 to less than 750 cells/mcL: 4%; 750 to less than 1000 cells/mcL: 8%) were reported during therapy or within 2 weeks of stopping therapy.

Very common (10% or more): Decreased hemoglobin (up to 41%), decreased platelets (up to 27%), decreased absolute neutrophil count (up to 19%)

Gastrointestinal

Very common (10% or more): Nausea (27%), diarrhea (26%), vomiting (19%), abdominal pain (12%)

Renal

Increased serum creatinine (greater than 2.5 mg/dL: 2%; greater than 1.5 to 2.5 mg/dL: 17%) was reported during therapy or within 2 weeks of stopping therapy.

Very common (10% or more): Increased serum creatinine (up to 17%)

Other

Very common (10% or more): Peripheral edema (14%), fatigue (13%)

Nervous system

Very common (10% or more): Headache (14%)

Uncommon (0.1% to 1%): Dysgeusia, vertigo

Respiratory

Very common (10% or more): Cough (14%)

Frequency not reported: Dyspnea

Cardiovascular

Common (1% to 10%): Tachycardia, atrial fibrillation

The cardiac side effect rate was higher in patients using this drug (13%) compared to those using placebo (6%). Tachycardia (4% [compared to 2% with placebo]) and atrial fibrillation (3% [compared to 1% with placebo]) were the most commonly reported cardiac side effects. Most cardiac side effects were reported as mild or moderate in severity.

Hypersensitivity

Uncommon (0.1% to 1%): Hypersensitivity reaction

After switching from the oral formulation, hypersensitivity reaction (associated with moderate dyspnea) was reported in 1 patient after the first IV infusion; as a result, treatment was discontinued.

Hepatic

Uncommon (0.1% to 1%): Increased ALT, increased AST

Metabolic

Uncommon (0.1% to 1%): Decreased appetite

Musculoskeletal

Uncommon (0.1% to 1%): Muscle spasms

Editorial References and Review

Medically reviewed by BestRx Medical Team Last updated on 1/1/2020.

Source: Drugs.com Prevymis